Prologis Inc vs Vir Biotechnology Inc. Common Stock — how do they compare? Prologis Inc trades at $131.99 (market cap $126.92B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Prologis Inc is far larger — about 70.5× Vir Biotechnology Inc. Common Stock's market cap, and Prologis Inc pays a 3.2% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| PLD | VIR | |
|---|---|---|
Market Cap | $126.92B | $1.80B |
Volume | 4,456,134 | 1,782,836 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $11.78 |
52-Week Low | $121.17 | $5.12 |
Typical Hold Time | 102 Days | 0 Days |
Enterprise Value | $161.66B | $1.36B |
Dividend Yield | 3.2% | — |
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $130.53, down 1.46% on the day, with strong fundamentals including 45.79% net income margin and consistent earnings beats. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages, trading near support at $130. Recent news highlights leasing growth and data center expansion opportunities, while institutional buying continues.
Outlook remains positive with 61.9% analyst buy ratings and $155.15 consensus target offering 19% upside. Key risks include elevated valuation multiples (P/E 29.74) and rising debt-to-asset ratio (37.2% in 2025). The company's logistics real estate portfolio benefits from e-commerce and data center demand trends.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →